# What Amyloid Beta Ratios in Blood Can Reveal Before a Scan Changes

- Article ID: research-003
- Product: A4 Amyloid Beta (a4-amyloid-beta-479)
- Canonical page: https://heritagebiolabs.com/research-library/articles/003-what-amyloid-beta-ratios-in-blood-can-reveal-before-a-scan-changes
- Product collection: https://heritagebiolabs.com/research-library/products/a4-amyloid-beta
- Product page: https://heritagebiolabs.com/product/a4-amyloid-beta-479
- Reading focus: Study findings (Reading focus is a navigational tag, not an evidence grade.)
- Source years: 2026

> Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend.

Peptides are amino acids linked by peptide bonds. Their amounts can sometimes be measured in a fluid sample and used as clues about a biological process. The amyloid beta family includes Aβ42 and Aβ40, two products of the same precursor that differ in length. The ratio of those two forms in plasma is a measurement of circulating peptides. An amyloid PET scan, by contrast, measures a tracer signal associated with deposited amyloid in the brain. The two tests do not sample the same material. [1, 2]

Azadeh Feizpour and colleagues studied 507 adults who had no cognitive impairment at enrollment and had brain amyloid measurements below the study's positive PET threshold. They measured baseline plasma Aβ42/40 using mass spectrometry and followed participants with repeat scans. Among people in the lowest PET category, those with an abnormal plasma ratio were more likely to cross the study's positive PET threshold during follow-up. About 19 percent of participants with an abnormal plasma ratio and a negative baseline scan progressed to PET positivity. Accounting for age, sex, APOE ε4 status and baseline scan burden reduced the estimated association but did not remove it. [1]

A separate 2026 analysis by Rodrigo Cánovas and colleagues used two mass spectrometry assays across four cohorts. Its modeling placed the average plasma ratio change before clear scan positivity, with variation related to APOE ε4. The date or age estimated for a group should not be read as a clock for an individual. The result depends on the assay, thresholds and the population being modeled. [2]

These studies help explain why a positive blood result and a negative scan are not automatically contradictory. They can reflect a difference in what each method detects and when it detects it. They can also disagree for reasons other than biological timing. A person with an abnormal result does not necessarily develop a positive scan, symptoms or dementia. One possible research use is selecting people for confirmatory imaging in prevention studies; Feizpour's group modeled a reduction in the number of scans needed for a particular enrollment strategy. That is a question about study design, not a demonstration that blood testing itself prevents disease. [1, 2]

## Sources

1. Feizpour A et al. Plasma Aβ42/40 predicts progression from Aβ-amyloid negative to positive PET scans. Journal of Prevention of Alzheimer's Disease (online 2026-01-01). <https://pubmed.ncbi.nlm.nih.gov/41478830/>
2. Cánovas R et al. When Does Alzheimer's Disease Start? Plasma Aβ42/40 Assays Show Steep Changes at Aβ-PET Centiloid 15, Mean Age of 66 Years. Annals of Neurology (online 2026-01-26). <https://pubmed.ncbi.nlm.nih.gov/41586468/>

## Provenance

Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed. Source volume: Peptide Research Articles 001 - A4 Amyloid Beta.docx; article 3; content SHA-256 f6fccdc6a9a7ca10297fe6a9dcbe565c67e733544ded228596eb6002d8214e70.
